Genocea Biosciences, Inc.

Clovis Oncology has warned it is “increasingly probable” that it will enter bankruptcy as revenues shrink and the regulatory outlook worsens for its only marketed drug, Rubraca. The Bolder, CO-based

The US stock market has been brutal for biopharmaceutical companies during the past year, with plummeting valuations driving companies to reprioritize their research and development plans, lay off emp

Cambridge, MA-based biotech company Genocea Biosciences has closed down operations and made its remaining employees redundant after running out of cash. Genocea is the second NASDAQ-listed biotech t

Restructuring announcements and plans to lay off significant numbers of employees unfortunately have become the norm rather than the exception in 2022 as biopharmaceutical company stock prices sink an